US6197786B1
(en)
*
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
GT199900147A
(es)
*
|
1998-09-17 |
1999-09-06 |
|
1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
|
US6147089A
(en)
*
|
1998-09-17 |
2000-11-14 |
Pfizer Inc. |
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
|
US7115279B2
(en)
|
2000-08-03 |
2006-10-03 |
Curatolo William J |
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
SE0101161D0
(sv)
*
|
2001-03-30 |
2001-03-30 |
Astrazeneca Ab |
New compounds
|
JP4334233B2
(ja)
*
|
2001-04-11 |
2009-09-30 |
アセロジエニクス・インコーポレイテツド |
プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法
|
ES2256461T3
(es)
*
|
2001-04-30 |
2006-07-16 |
Pfizer Products Inc. |
Compuestos utiles como intermediarios de derivados de 4-aminoquinolina.
|
TNSN03139A1
(fr)
*
|
2001-06-21 |
2005-12-23 |
Pfizer Prod Inc |
Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle
|
EA006777B1
(ru)
*
|
2001-06-22 |
2006-04-28 |
Пфайзер Продактс Инк. |
Фармацевтические композиции адсорбатов аморфного лекарственного средства
|
EP1404300B1
(fr)
|
2001-06-22 |
2009-09-30 |
Pfizer Products Inc. |
Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
|
EP1269994A3
(fr)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
|
WO2003053359A2
(fr)
|
2001-12-19 |
2003-07-03 |
Atherogenics, Inc. |
1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
|
RU2004121898A
(ru)
*
|
2001-12-19 |
2006-01-20 |
Атеродженикс, Инк. (Us) |
Производные халкона и их применение для лечения заболеваний
|
AU2002351748B2
(en)
*
|
2001-12-21 |
2009-07-09 |
Novo Nordisk A/S |
Amide derivatives as GK activators
|
PT1469833T
(pt)
*
|
2002-02-01 |
2021-07-13 |
Bend Res Inc |
Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
ES2309294T3
(es)
*
|
2002-02-01 |
2008-12-16 |
Pfizer Products Inc. |
Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
|
ATE395044T1
(de)
*
|
2002-02-01 |
2008-05-15 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
|
WO2004002481A1
(fr)
*
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Activateurs de la glycokinase
|
US20040053842A1
(en)
*
|
2002-07-02 |
2004-03-18 |
Pfizer Inc. |
Methods of treatment with CETP inhibitors and antihypertensive agents
|
US7071210B2
(en)
*
|
2002-07-02 |
2006-07-04 |
Pfizer Inc. |
CETP inhibitors in combination with antihypertensive agents and uses thereof
|
US20090181966A1
(en)
*
|
2002-10-04 |
2009-07-16 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US7504508B2
(en)
|
2002-10-04 |
2009-03-17 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
US7211672B2
(en)
*
|
2002-10-04 |
2007-05-01 |
Millennium Pharmaceuticals, Inc. |
PGD2 receptor antagonists for the treatment of inflammatory diseases
|
CA2500083A1
(fr)
*
|
2002-10-21 |
2004-04-29 |
Warner-Lambert Company Llc |
Derives de tetrahydroquinoline antagonistes de crth2
|
WO2004052863A1
(fr)
*
|
2002-12-06 |
2004-06-24 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-inflammatoire
|
AU2003303239A1
(en)
*
|
2002-12-19 |
2004-07-14 |
Atherogenics, Inc. |
Process of making chalcone derivatives
|
BR0317521A
(pt)
|
2002-12-20 |
2005-11-16 |
Pfizer Prod Inc |
Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
EP1435356A1
(fr)
*
|
2003-01-06 |
2004-07-07 |
Warner-Lambert Company LLC |
Dérivés de la quinoléine en tant qu'antagonistes de CRTH2
|
WO2004072042A2
(fr)
*
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Modulation de l'activite de recepteurs nucleaires
|
BRPI0408442A
(pt)
*
|
2003-03-17 |
2006-04-04 |
Japan Tobacco Inc |
método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
|
PT1603553E
(pt)
|
2003-03-17 |
2012-02-03 |
Japan Tobacco Inc |
Composições farmacêuticas de inibidores de cetp
|
US20040204450A1
(en)
*
|
2003-03-28 |
2004-10-14 |
Pfizer Inc |
Quinoline and quinoxaline compounds
|
JP2006521344A
(ja)
*
|
2003-03-28 |
2006-09-21 |
ファイザー・プロダクツ・インク |
アテローム性動脈硬化症および肥満の治療のためのcetp阻害剤としての1,2,4−置換1,2,3,4−テトラヒドロ−および1,2−ジヒドロ−キノリンおよび1,2,3,4−テトラヒドロ−キノキサリン誘導体
|
TWI494102B
(zh)
*
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
EA009646B1
(ru)
|
2003-05-30 |
2008-02-28 |
Рэнбакси Лабораториз Лтд. |
Замещённые производные пиррола и их применение в качестве ингибиторов hmg-coa
|
JP2007501218A
(ja)
|
2003-08-04 |
2007-01-25 |
ファイザー・プロダクツ・インク |
非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
EP2319509A1
(fr)
|
2003-09-26 |
2011-05-11 |
Japan Tobacco, Inc. |
Méthodes pour inhiber la production de lipoprotéines rémanents
|
CA2540231A1
(fr)
*
|
2003-09-30 |
2005-04-14 |
Pfizer Products Inc. |
Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
|
DK1670768T3
(da)
*
|
2003-10-08 |
2009-11-09 |
Lilly Co Eli |
Forbindelser og fremgangsmåder til at behandle dyslipidæmi
|
CA2543596A1
(fr)
*
|
2003-11-07 |
2005-05-26 |
Jj Pharma, Inc. |
Complexes pour une therapie combinatoire stimulant les hdl
|
BRPI0506662B8
(pt)
|
2004-01-06 |
2021-05-25 |
Novo Nordisk As |
compostos ativadores de glucoquinase
|
SI1725234T1
(sl)
|
2004-03-05 |
2013-04-30 |
The Trustees Of The University Of Pennsylvania |
Postopki zdravljenja nepravilnosti ali bolezni povezanih s hiperlipidemijo in hiperholesterolemijo z minimiziranjem stranskih uäśinkov
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
BRPI0508966A
(pt)
|
2004-03-26 |
2007-08-21 |
Lilly Co Eli |
composto, composição farmacêutica, e, uso de um composto
|
TWI345568B
(en)
*
|
2004-04-02 |
2011-07-21 |
Mitsubishi Tanabe Pharma Corp |
Tetrahydronaphthyridine derivatives and a process for preparing the same
|
UA90269C2
(ru)
*
|
2004-04-02 |
2010-04-26 |
Мицубиси Танабе Фарма Корпорейшн |
Тетрагидрохинолиновые производные и способ их получения
|
WO2006009819A1
(fr)
*
|
2004-06-18 |
2006-01-26 |
Array Biopharma Inc. |
Inhibiteurs de proteines de transfert d'ester de cholesteryle
|
KR100859223B1
(ko)
*
|
2004-06-24 |
2008-09-18 |
일라이 릴리 앤드 캄파니 |
이상지혈증 치료를 위한 화합물 및 방법
|
EP1761521A1
(fr)
*
|
2004-06-24 |
2007-03-14 |
Eli Lilly And Company |
Composés et procédés destinés à traiter la dyslipidémie
|
WO2006004903A2
(fr)
*
|
2004-06-28 |
2006-01-12 |
Atherogenics, Inc. |
1,2-bis-(phenyl-substitue)-2-propen-1-ones et des compositions pharmaceutiques en contenant
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
AU2005280058B2
(en)
*
|
2004-08-25 |
2010-09-02 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
WO2006033004A1
(fr)
*
|
2004-09-23 |
2006-03-30 |
Pfizer Products Inc. |
Composes de quinoline en tant qu'inhibiteurs de cetp
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
MX2007005137A
(es)
*
|
2004-11-23 |
2007-06-22 |
Warner Lambert Co |
Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
|
US7700774B2
(en)
*
|
2004-12-20 |
2010-04-20 |
Dr. Reddy's Laboratories Ltd. |
Heterocyclic compounds and their pharmaceutical compositions
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
WO2006073973A2
(fr)
|
2004-12-31 |
2006-07-13 |
Reddy Us Therapeutics, Inc. |
Nouveaux dérivés de benzylamine en tant qu'inhibiteurs de cetp
|
EP1844078B1
(fr)
|
2005-02-03 |
2016-09-28 |
Bend Research, Inc |
Compositions pharmaceutiques a efficacite amelioree
|
WO2006091674A1
(fr)
|
2005-02-24 |
2006-08-31 |
Millennium Pharmaceuticals, Inc. |
Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires
|
WO2006098394A1
(fr)
*
|
2005-03-14 |
2006-09-21 |
Japan Tobacco Inc. |
Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
|
CN102757397A
(zh)
*
|
2005-07-01 |
2012-10-31 |
默沙东公司 |
合成cetp抑制剂的方法
|
JP2009500377A
(ja)
*
|
2005-07-08 |
2009-01-08 |
ノボ・ノルデイスク・エー/エス |
ジシクロアルキルウレア型グルコキナーゼ活性化剤
|
JP2009500378A
(ja)
*
|
2005-07-08 |
2009-01-08 |
ノボ・ノルデイスク・エー/エス |
グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
|
US7884210B2
(en)
*
|
2005-07-14 |
2011-02-08 |
Novo Nordisk A/S |
Ureido-thiazole glucokinase activators
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
JP4531027B2
(ja)
*
|
2005-09-29 |
2010-08-25 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4681526B2
(ja)
*
|
2005-09-29 |
2011-05-11 |
田辺三菱製薬株式会社 |
医薬組成物
|
CA2625416A1
(fr)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combinaison de composes organiques
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
ES2374963T3
(es)
|
2006-01-05 |
2012-02-23 |
Essentialis, Inc. |
Sales de agentes de apertura del canal de potasio dependiente de atp y usos de las mismas.
|
UY30117A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compuesto amina trisustituido
|
PE20071025A1
(es)
|
2006-01-31 |
2007-10-17 |
Mitsubishi Tanabe Pharma Corp |
Compuesto amina trisustituido
|
TW200808731A
(en)
|
2006-03-30 |
2008-02-16 |
Tanabe Seiyaku Co |
A process for preparing tetrahydroquinoline derivatives
|
GB0615670D0
(en)
*
|
2006-08-07 |
2006-09-13 |
Syngenta Participations Ag |
Chemical compounds
|
US7750019B2
(en)
|
2006-08-11 |
2010-07-06 |
Kowa Company, Ltd. |
Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
|
CL2007002958A1
(es)
*
|
2006-10-12 |
2008-05-09 |
Epix Delaware Inc |
Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
US20080161279A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
JP2010515701A
(ja)
*
|
2007-01-09 |
2010-05-13 |
ノボ・ノルデイスク・エー/エス |
ウレアグルコキナーゼアクチベーター
|
JP5226008B2
(ja)
|
2007-01-11 |
2013-07-03 |
ノボ・ノルデイスク・エー/エス |
ウレアグルコキナーゼアクチベーター
|
CN101220021B
(zh)
*
|
2007-01-12 |
2010-12-08 |
上海医药工业研究院 |
4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
|
US7790737B2
(en)
|
2007-03-13 |
2010-09-07 |
Kowa Company, Ltd. |
Substituted pyrimidine compounds and their utility as CETP inhibitors
|
HUE024898T2
(en)
|
2007-04-13 |
2016-02-29 |
Kowa Co |
New pyrimidine compound with dibenzylamine structure and drug containing compound
|
CA2692160A1
(fr)
*
|
2007-07-02 |
2009-01-08 |
Essentialis, Inc. |
Sels d'ouvreurs de canaux potassiques sensibles a l'atp et leurs utilisations
|
AU2008324243B2
(en)
|
2007-11-05 |
2012-03-08 |
Novartis Ag |
4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
|
ES2425776T3
(es)
|
2007-12-03 |
2013-10-17 |
Novartis Ag |
Derivados 1,2-disustituidos de 4-bencilamino-pirrolidina como inhibidores CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis
|
AU2008335135A1
(en)
|
2007-12-11 |
2009-06-18 |
Cytopathfinder, Inc. |
Carboxamide compounds and their use as chemokine receptor agonists
|
JP5654572B2
(ja)
|
2009-05-15 |
2015-01-14 |
ノバルティス アーゲー |
アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
|
MA33358B1
(fr)
|
2009-05-15 |
2012-06-01 |
Novartis Ag |
Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
|
MA33364B1
(fr)
|
2009-05-28 |
2012-06-01 |
Novartis Ag |
Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
|
ES2602826T3
(es)
|
2009-05-28 |
2017-02-22 |
Novartis Ag |
Derivados aminobutíricos sustituidos como inhibidores de neprilisina
|
TWI450896B
(zh)
*
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸
|
US8519134B2
(en)
|
2009-11-17 |
2013-08-27 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(fr)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Dérivés d'imidazole en tant qu'inhibiteurs de l'aldostérone synthase
|
US20130072519A1
(en)
|
2010-05-21 |
2013-03-21 |
Edward Lee Conn |
2-phenyl benzoylamides
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
WO2012101142A1
(fr)
|
2011-01-26 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
|
EP2680874A2
(fr)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Peptides de type edn3 et utilisations associées
|
KR101599157B1
(ko)
|
2011-06-17 |
2016-03-02 |
머크 샤프 앤드 돔 코포레이션 |
Crth₂ 수용체 조절제로서의 시클로알킬-융합된 테트라히드로퀴놀린
|
AR087451A1
(es)
*
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
WO2013024358A2
(fr)
|
2011-08-18 |
2013-02-21 |
Dr. Reddy's Laboratories Ltd. |
Composés amines hétérocycliques substitués comme inhibiteurs de la protéine de transfert d'ester cholesterylique (cetp)
|
CN103958511A
(zh)
|
2011-09-27 |
2014-07-30 |
雷迪博士实验室有限公司 |
作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
|
MX347400B
(es)
|
2012-06-29 |
2017-04-18 |
Univ Nac Autónoma De México |
Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
AP2015008621A0
(en)
|
2013-02-14 |
2015-07-31 |
Novartis Ag |
Substituted bisphenyl butanoic nep 'neutral endopeptidase' inhibitors
|
CN105143203A
(zh)
|
2013-04-17 |
2015-12-09 |
辉瑞大药厂 |
用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
|
UY35670A
(es)
|
2013-07-25 |
2015-02-27 |
Novartis Ag |
Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
|
JP2016527249A
(ja)
|
2013-07-25 |
2016-09-08 |
ノバルティス アーゲー |
合成アペリンポリペプチドのバイオコンジュゲート
|
WO2016032324A1
(fr)
*
|
2014-08-28 |
2016-03-03 |
Dezima Pharma B.V. |
Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
|
DK3186242T3
(da)
|
2014-08-29 |
2021-12-20 |
Tes Pharma S R L |
Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
|
WO2016055901A1
(fr)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Composés d'amide substitué
|
KR20170103970A
(ko)
|
2015-01-23 |
2017-09-13 |
노파르티스 아게 |
개선된 반감기를 갖는 합성 아펠린 지방산 접합체
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
MX2020008905A
(es)
|
2018-06-12 |
2020-12-03 |
Vtv Therapeutics Llc |
Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
|
CN113574055B
(zh)
|
2019-01-18 |
2024-07-23 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|